Optimi Health Establishes Australian Subsidiary
The company is expanding its operations to supply psilocybin and MDMA capsules under Australia's Authorised Prescriber Scheme.
Updated on Oct. 26, 2026 in Australia and New Zealand
Live Poll
Do you support the increased availability of regulated psychedelic drugs for clinical use in your country?
Optimi Health Corp has launched a wholly owned Australian subsidiary, Optimi Australia Pty Ltd, to manage sales and distribution in the country. The move aims to meet growing demand for controlled substance therapies from authorized prescribers.
Why it matters
This expansion allows the company to establish a direct presence in the Australian market, facilitating the supply of specialised therapies. It marks a strategic step toward increasing access for clinics and pharmacies operating under local clinical frameworks.
The new subsidiary will supply 5mg psilocybin capsules alongside 40mg and 60mg MDMA capsules. These products are currently manufactured at a Health Canada-licensed GMP facility located in Princeton, British Columbia.
The players
Optimi Health Corp
A company based in Vancouver, British Columbia, that focuses on the production and distribution of pharmaceutical-grade controlled substances.
Adrian Jones
The newly appointed Director of Australian Operations who previously served as the Associate Director and Head of Sales and Marketing for Bristol Myers Squibb for over 15 years.
The details
Optimi Australia Pty Ltd will handle all prescriber relationships and commercial operations within the country to streamline product distribution. The entity operates under the Authorised Prescriber Scheme, focusing on growing its network of participating clinics and pharmacies.
Timeline
Optimi Australia Pty Ltd was officially established on 26 October 2026.
Travel Outlook
This move aligns with Australia's Authorised Prescriber Scheme, which governs the legal framework for prescribing controlled substances like psilocybin and MDMA. It reflects an evolving regulatory environment that increasingly permits specialized medical supply chains in the region.
Medical professionals and clinics within Australia can now engage directly with the subsidiary to manage supply requests for authorized patient therapies. The company is currently building out its local network to improve the consistency of access for pharmacies and clinics.
The takeaway
This entry into the Australian market highlights the growing commercial infrastructure supporting the distribution of controlled medical substances. Interested healthcare providers should monitor the subsidiary's updates as it rolls out its full distribution network.
Further reading
For more information on regional medical developments, visit the Australia and New Zealand section.
More information
For official details on the company's local offerings, visit the Optimi Australia website.
Source note: This article includes information reported by Financial Post.
Live Poll
Do you support the increased availability of regulated psychedelic drugs for clinical use in your country?
